WeHans

WeHans Biomedical was founded in 2016, focusing on genetic disease screening and diagnosis, miscarriage product testing, and de novo mutation single-gene blocking*. It serves as a Shanghai municipal technology service platform for genetic disease gene testing and tertiary prevention of birth defects. The company is headquartered in Shanghai International Medical Zone, with an independent third-party medical laboratory (LDT/Shanghai), an IVD (genetic testing kits and equipment) and POCT production base (equipment and supporting testing reagents). Its business covers genetic disease screening (tertiary prevention), assisted diagnosis of genetic diseases, infertility and miscarriage product testing, non-invasive prenatal single-gene disease testing (NIPT-M), single-gene disease blocking testing (PGT-M), and scientific research collaboration in genetic diseases. The company has established solid cooperative relationships with hundreds of top medical institutions and experts. It operates various testing platforms for genetic diseases: Sanger sequencing, next-generation sequencing (Illumina, BGI), Bionano (structural variation), QPCR, etc., providing complete solutions for genetic disease testing and research. The company holds 31 patents, 33 software copyrights, 43 trademarks, 30 medical device registration certificates, and 26 CE certifications. The company has completed several rounds of financing from well-known institutions such as China Renaissance, Huayao Capital, and Shengshan Assets.